Parker H. “Pete” Petit, the former chief executive officer of wound care company MiMedx was convicted of fraud and making false statements to the U.S. Securities and Exchange Commission, following a months-long investigation into the company’s financial records. William Taylor, the company’s former chief operating officer, was also found guilty.

SR One has backed biotech companies for decades as GlaxoSmithKline’s venture arm. Now, the firm is striking out on its own, having spun out from the British conglomerate and raised a whopping $500 million fund.

San Francisco-based breast cancer biotech Olema Oncology has priced its initial public offering (IPO) of 11,000,000 common shares at a public price of $19.00 per share, a price the company expects to lead to gross proceeds of $209.0 million.

SynOx Therapeutics has raised €37 million ($44 million) to advance a drug licensed from Roche. The series A tees SynOx up to build on signs the anti-CSF1R monoclonal antibody improves outcomes in patients with tenosynovial giant cell tumors (TGCTs).

Patients diagnosed with myeloproliferative neoplasm, a group of blood cancers in which the body overproduces red or white blood cells, don’t have great options. Treatment tends to be palliative, without changing the course of disease. Enter Imago BioSciences, which is working on a treatment that shuts down an enzyme important to cancer growth.

D3 Bio has emerged with $200 million from a syndicate of heavy hitters and an ex-AstraZeneca leader in the CEO role. George Chen, M.D., set up D3 Bio after seven years at AstraZeneca and persuaded investors including Sequoia Capital China and Temasek to bankroll his plans. 

As colleagues at Seattle Children’s Hospital, Andy Scharenberg, M.D., and Michael Jensen, M.D., knew they wanted to build a startup with a mission.

Retrophin may have ousted Martin Shkreli back in 2014, but he kept reappearing, last year suing—and settling with—the management of his former company, all from a prison cell. Now, the rare disease biotech is turning the page for good with a new identity: Travere Therapeutics.

Elevation Oncology has raised $65 million to complete enrollment in a registration-enabling phase 2 cancer trial. The study is assessing seribantumab, an anti-HER3 antibody that failed multiple trials at Merrimack Pharmaceuticals before being reborn as a tumor-agnostic candidate at Elevation.

CymaBay Therapeutics is getting its liver disease drug back on track. The treatment beat placebo at lowering a liver enzyme in patients with primary biliary cholangitis (PBC), a rare, progressive disease that can lead to inflammation and scarring in the liver. The data come one year after the company halted all clinical development of the drug, seladelpar, and four months after it resurrected the program.